GNF2133
CAS No. 2561414-56-8
GNF2133( —— )
Catalog No. M28282 CAS No. 2561414-56-8
GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 357 | In Stock |
|
| 5MG | 312 | In Stock |
|
| 10MG | 471 | In Stock |
|
| 25MG | 787 | In Stock |
|
| 50MG | 1144 | In Stock |
|
| 100MG | 1609 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGNF2133
-
NoteResearch use only, not for human use.
-
Brief DescriptionGNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.
-
DescriptionGNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.(In Vitro):GNF2133 has an IC50 of >50 μM for GSK3β. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion.(In Vivo):In Diphtheria toxin A (RIP-DTA) mice, GNF2133 (3, 10, 30 mg/kg) significantly improves glucose disposal capacity and increased insulin secretion. In CD-1 mice, GNF2133 (30 mg/kg; p.o.) shows moderate plasma exposure and good oral absorption with oral bioavailability of 22.3%. In Wistar Han rat, GNF2133 (30 mg/kg; p.o.) increases in cell proliferation marker Ki67 and insulin and reduces cyclin D1 levels and overall cell density.
-
In Vitro——
-
In VivoGNF2133 (30 mg/kg; p.o.) shows good oral absorption with oral bioavailability of 22.3%.GNF2133 (30 mg/kg; p.o.; once a day for 5 days) shows the ability to proliferate β-cells in vivo.GNF2133 (3, 10, 30 mg/kg) significantly improves glucose disposal capacity and increased insulin secretion in RIP-DTA mice.Pharmacokinetic Parameters of GNF2133 in CD-1 mice.CD-1 mice; 30 mg/kg; p.o.. Animal Model:CD-1 mice Dosage:30 mg/kg Administration: P.o.Result:Showed good oral absorption and moderate plasma exposure with oral bioavailability of 22.3%.Animal Model:Wistar Han rat Dosage:30 mg/kg (0.5% methylcellulose + Tween-80)Administration:P.o.; once a day for 5 days Result:Increased cyclin D1 levels and overall cell density, and increased in cell proliferation marker Ki67 and insulin.Animal Model:Diphtheria toxin A (RIP-DTA) miceDosage:3, 10, 30 mg/kg (20 mg/kg doxycycline (Dox) for 5 days)Administration:P.o., once a day for 35 daysResult:Significantly improves glucose disposal capacity and increased insulin secretion.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorVEGFR|Tyrosine Kinases
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2561414-56-8
-
Formula Weight434.53
-
Molecular FormulaC24H30N6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 4 mg/mL (9.21 mM)
-
SMILESO=C(NC1=NC=CC(=C1)C2=CN(C=3C=NC=CC23)C4CCOCC4)N5CCN(CC)CC5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yukitsuka Kudo, et al. Benzoxazole derivatives. US7910579B2
molnova catalog
related products
-
[Lys1015,1024]-Throm...
4N1K peptide is a biological active peptide. (4N1K-peptide (KRFYVVMWKK), which is derived from thrombospondins has anti-cancer activities in several cancers)
-
Abscisic acid
Abscisic acid is a compound isolated from fruits and plants.
-
Cholecystokinin Octa...
Cholecystokinin Octapeptide (1-2) (desulfated) (H-Asp-Tyr-OH) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.
Cart
sales@molnova.com